

DCS & NYSIF PRESCRIPTION DRUG PROGRAMS
Pharma Revenue Guarantee Quote
 Period 1/1/2019 - 12/31/2023

Pharma Revenue Guarantee (1)	Per Final Paid Claim (DCS Program)	Per Final Paid Claim (NYSIF)
2019	\$ _____	\$ _____
2020	\$ _____	\$ _____
2021	\$ _____	\$ _____
2022	\$ _____	\$ _____
2023	\$ _____	\$ _____

(1) The quote above represents the guaranteed minimum amount due the Programs.

- The State shall receive all (100%) of Pharma Revenue as defined in this RFP.
- The amount must be quoted on a per final paid claim basis, as defined in Section VIII (the glossary).
- No separate administrative fee to manage the Pharma Revenue process shall apply.

The Offeror's Minimum Per Final Paid Claim Pharma Revenue Guarantee Quote is not contingent upon the Programs' participation in any of the Offeror's formulary management or intervention programs, including step therapy. The Offeror may not make such quotes contingent upon use of their Book of Business Formulary. Nor shall the Offeror's Minimum Per Final Paid Claim Pharma Revenue Guarantee Quote be contingent or dependent on the timing of any patent expirations and/or introduction of generic equivalent drugs, including but not limited to early and/or at risk generic launches.

Note:

Offerors must provide adequate documentation as determined by the Procuring Agencies, to support the Offeror's proposal relative to pharma revenue. Documentation should be provided as Exhibit V.E.1 of the Offeror's proposal.